

Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response

Bryan J. Schneider¹, Manish A. Shah¹, Kelsey Klute¹, Allyson Ocean¹, Elizabeta Popa¹, Nasser Altorki², Michael Lieberman³, Andrew Schreiner⁴, Rhonda Yantiss⁴, Paul J. Christos⁵, Romae Palmer⁶, Daoqi You⁷, Agnes Viale⁷, Pouneh Kermani¹, and Joseph M. Scandura^{1,8}

Abstract

Purpose: Epigenetic silencing of tumor suppressor genes (TSG) is an acquired abnormality observed in cancer and is prototypically linked to DNA methylation. We postulated that pretreatment (priming) with 5-azacitidine would increase the efficacy of chemotherapy by reactivating TSGs. This study was conducted to identify a tolerable dose of 5-azacitidine prior to EOX (epirubicin, oxaliplatin, capecitabine) neoadjuvant chemotherapy in patients with locally advanced esophageal/gastric adenocarcinoma (EGC).

Experimental Design: Eligible patients had untreated, locally advanced, resectable EGC, ECOG 0–2, and adequate organ function. 5-Azacitidine (V, 75 mg/m²) was given subcutaneously for 3 (dose level, DL 1) or 5 (DL 2) days prior to each 21-day cycle of EOX (E, 50 mg/m²; O, 130 mg/m²; X, 625 mg/m² twice daily for 21 days). Standard 3+3 methodology guided V dose escalation. DNA methylation at control and biomarker regions was measured

by digital droplet, bisulfite qPCR in tumor samples collected at baseline and at resection.

Results: All subjects underwent complete resection of residual tumor (R0). Three of the 12 patients (25%) achieved a surgical complete response and 5 had partial responses. The overall response rate was 67%. The most common toxicities were gastrointestinal and hematologic. Hypomethylation of biomarker genes was observed at all dose levels and trended with therapeutic response.

Conclusions: Neoadjuvant VEOX was well-tolerated with significant clinical and epigenetic responses, with preliminary evidence that priming with V prior to chemotherapy may augment chemotherapy efficacy. The recommended phase II trial schedule is 5-azacitidine 75 mg/m² for 5 days followed by EOX chemotherapy every 21 days. *Clin Cancer Res*; 1–8. ©2016 AACR.

¹Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York. ²Department of Thoracic Surgery, Weill Cornell Medical College, New York, New York. ³Department of Surgery, Weill Cornell Medical College, New York, New York. ⁴Department of Pathology, Weill Cornell Medical College, New York, New York. ⁵Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York. ⁶Clinical Trials Office, Weill Cornell Medical College, New York, New York. ⁷Memorial Sloan-Kettering Cancer Center, New York, New York. ⁸Division of Regenerative Medicine, Department of Internal Medicine; Weill Cornell Medical College, New York, New York.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Prior Presentation: Poster presentation at ASCO Annual Meeting, Chicago, IL; May 31, 2014.

Corresponding Author: Bryan J. Schneider, C411 Med Inn Building, 1500 East Medical Center Drive, SPC 5848, Ann Arbor, MI 48019. Phone: 734-647-8921; Fax: 734-647-8792; E-mail: bryansch@med.umich.edu

doi: 10.1158/1078-0432.CCR-16-1896

©2016 American Association for Cancer Research.

Introduction

Epigenetic silencing of tumor suppressor genes (TSG) is commonly observed in gastroesophageal cancer and is believed to play a role in oncogenesis, metastasis, and chemotherapy resistance (1–7). 5-Azacitidine (V, Vidaza) is a cytosine analog that acts as a DNA hypomethylating agent (DHA) because it cannot accept a methyl donor in the 5'-position of the pyrimidine ring and depletes cellular DNA methyltransferase I (DNMT1). Reactivated expression of TSGs is commonly implicated in the clinical activity of DHAs, as TSGs often regulate apoptosis, DNA repair, and checkpoint control. *In vitro*, DHAs can sensitize resistant cancer cells to a variety of cytotoxic agents (8–11) including the most active chemotherapies for gastroesophageal cancer (platinum agents and epirubicin; refs. 10, 12–15). Yet this approach has been sparsely studied in clinical trials and has never been tested in esophageal/gastric adenocarcinoma (EGC).

We hypothesized that pretreatment (i.e., priming) with a hypomethylating agent will sensitize the adenocarcinoma to cytotoxic therapy and increase the efficacy of neoadjuvant chemotherapy by

Translational Relevance

This article describes an open-label, phase I study that we performed to explore the feasibility, safety, and biologic activity of epigenetic priming with 5-azacitidine prior to neoadjuvant epirubicin, oxaliplatin, and capecitabine chemotherapy in patients with potentially resectable esophageal/gastric cancer. Complete response is a requisite for the cure of esophageal and gastric adenocarcinoma, and this study demonstrates that it is safe to combine the epigenetic modifier azacitidine with full-dose, neoadjuvant, cytotoxic chemotherapy as an approach to improve complete response rates and improve survival. These findings provide the foundation for a subsequent phase II study to more clearly characterize the efficacy of epigenetic priming during neoadjuvant chemotherapy. We expect that this study defining the feasibility of epigenetic priming in gastric and esophageal adenocarcinoma will translate to therapeutic advances in more common forms of cancer, as transcriptional silencing of TSGs by DNA hypermethylation is seen in most, if not all, forms of cancer.

reactivating expression of chemotherapy-sensitizing TSGs during the window of exposure to cytotoxic agents. We previously found that "epigenetic priming" using a DHA prior to intensive chemotherapy for acute myelogenous leukemia (AML) showed favorable activity without additive toxicity, and this approach is currently being tested in a large, multicenter, randomized phase II study sponsored by NCI (clinicaltrials.gov NCT00538876 and NCT01627041; refs. 16, 17). Others have found that DHAs can be safely combined with chemotherapy for solid tumor malignancies, although experience is quite limited (18–22). We conducted an open-label phase I evaluation of the feasibility, safety, and biologic activity of epigenetic priming using the hypomethylating agent 5-azacitidine prior to full-dose, neoadjuvant epirubicin, oxaliplatin, and capecitabine (EOX) chemotherapy in patients with surgically resectable EGC (clinicaltrials.gov NCT01386346). Tumor DNA hypomethylation was analyzed in samples obtained before and following azacitidine treatment as a pharmacodynamic biomarker of epigenetic response.

Materials and Methods

Eligibility

Adult patients (age ≥ 18) with untreated, histologically confirmed locoregional adenocarcinoma of the intrathoracic esophagus, gastroesophageal junction, or stomach were eligible if they were deemed potentially resectable by the surgeon. Eligible patients had Zubrod performance status (PS) of 0–2, no baseline hematopoietic deficiencies (absolute neutrophil count (ANC) \geq

1,500/mm³, platelet count $\geq 100,000$ /mm³), and adequate organ function [serum creatinine $\leq 1.5 \times$ the institutional upper limit of normal (ULN), total bilirubin $\leq 1.5 \times$ ULN, and aspartate aminotransferase (AST)/alkaline aminotransferase (ALT) $\leq 2.0 \times$ ULN]. Patients were ineligible if they had squamous cell carcinoma or cervical esophageal cancer, congestive heart failure (New York Heart Association Class II or greater), active angina pectoris, or a myocardial infarction within 6 months or were unable to take oral medication. The trial was approved by the Weill Cornell Institutional Review Board and informed consent was obtained from all patients.

Drug and dosage administration

EOX chemotherapy included epirubicin 50 mg/m² and oxaliplatin 130 mg/m² on day 1 plus capecitabine 625 mg/m² (rounded to the nearest 500 mg) orally twice daily for a 21-day cycle. Patients received azacitidine (V) 75 mg/m² by subcutaneous injection daily for either 3 (DL 1) or 5 days (DL 2) and received EOX on the last day of azacitidine (Table 1). VEOX chemotherapy was given for 3 cycles prior to resection. Inpatient dose escalation/decrease of azacitidine was not allowed. Subsequent EOX doses were reduced if clinically significant day 12 (± 2 days) neutropenia or thrombocytopenia were observed. Additional dose reductions of EOX agents were allowed for hand-foot syndrome, mucositis, diarrhea, or neurotoxicity (Supplementary Table S1).

Dose-limiting toxicities (DLT) during the cycle 1 or 2 halted neoadjuvant chemotherapy for that patient. All toxicities must have returned to \leq grade 1 prior to beginning the next cycle of neoadjuvant chemotherapy and neutrophils and platelets much have recovered to $\geq 1,500/\mu\text{L}$ and $\geq 100,000/\mu\text{L}$, respectively. All patients underwent surgical resection 2 to 4 weeks from the last cycle of neoadjuvant VEOX. Postsurgical therapy was left to the discretion of the treating clinician. Azacitidine (V) was supplied by Celgene & Co., Inc. in 100-mg vials.

Trial design

A standard 3+3 phase I strategy was used to escalate the azacitidine dose level if the clinical toxicity was acceptable. Toxicities were graded according to the NCI Common Toxicity Criteria version 4.0 (23, 24). DLTs during the first cycle were defined as grade ≥ 3 nonhematologic toxicity (exceptions noted below), grade 4 neutropenia lasting more than 7 days, grade ≥ 3 neutropenia associated with sepsis or fever $> 38^\circ\text{C}$, grade 4 thrombocytopenia, or more than a 2-week toxicity-related delay in starting cycles 2 or 3. Exceptions to the DLT definition included: alopecia; nausea and vomiting lasting less than 48 hours; grade 3 fatigue lasting less than 21 days; grade 3 diarrhea lasting less than 7 days; or nonhematologic laboratory abnormalities that did not alter clinical management; or were not treatment-related. During the second cycle, the following

Table 1. VEOX dosing schedule

Agent	Day -4	Day -3	Day -2	Day -1	Day +1	Day +2 to 21
Dose level 1: azacitidine			75 mg/m ²	75 mg/m ²	75 mg/m ²	
Dose level 2: azacitidine	75 mg/m ²					
Oxaliplatin					130 mg/m ²	
Epirubicin					50 mg/m ²	
Capecitabine					625 mg/m ² BID	625 mg/m ² BID ^a

NOTE: Cycles were repeated every 21 days for a total of 3 neoadjuvant cycles.

^aCapecitabine was taken daily starting on cycle 1 day +1 and continued uninterrupted for 9 weeks as tolerated.

additional DLT criteria were used: any toxicity requiring more than one dose reduction in any EOX chemotherapeutic agent; nonhematologic toxicity requiring dose reductions in more than 2 EOX chemotherapeutic agents.

Patients were considered evaluable for response if they received at least one cycle of VEOX. Patients underwent positron emission tomography (PET/CT) after 3 cycles of treatment, prior to resection. Response was determined both by PERCIST criteria (radiographic response) and by analysis of the resected specimen (pathologic response; ref. 25).

Statistical analysis

The primary objective was to identify a maximum tolerated dose (MTD) of azacitidine as defined as the highest dose level with an observed incidence of DLT in no more than 1 of 6 patients. An additional 3 or 6 subjects (for a total of up to 9 subjects) were treated at the MTD—or at the highest dose if an MTD was not determined—to further assess potential toxicities.

Secondary exploratory objectives included radiographic and pathologic response rates, frequency of R0 surgery, overall (OS) and disease-free survival (DFS), and analysis of the epigenetic and cellular effects of azacitidine priming. Disease-free survival time was calculated from initiation of preoperative chemotherapy until the first occurrence of documented disease recurrence, progression (including development of metastatic disease), or death from any cause. The Kaplan–Meier method was used to estimate OS and DFS. Greenwood's formula was used to calculate 95% confidence intervals (CI) for Kaplan–Meier survival estimates. All subjects were evaluable for toxicity from the time of their first dose of azacitidine and were assessed for response to experimental treatment. Demographic and baseline disease characteristics were summarized descriptively for all subjects. Severe adverse events (SAE) and efficacy were summarized for the entire population and within dosing cohorts. Analyses were performed in SPSS Version 22.0 (SPSS Inc.), Stata Version 13.0 (StataCorp), or custom R scripts.

Analysis of DNA methylation

Bisulfite digital droplet PCR (BS-ddPCR) was used to assess DNA methylation at selected loci that are constitutively methylated (*HIST1H2AA*; ref. 17) or abnormally methylated in many esophageal and gastric carcinomas (*CDKN2A*, *ESR1*, *HPP1/TMEFF2*, *MGMT*, *TIMP3*; refs. 4, 26). Bisulfite-specific PCR primers that are insensitive to DNA methylation were used for a normalizing control (*ACTB*; ref. 4). Genomic DNA was purified from the diagnostic tumor specimen and the resection specimen to measure the *in vivo* effect of azacitidine on DNA methylation. DNA was extracted from each section, quantified with picoGreen (Life Tech), and bisulfite-converted (Zymo Research). Sss1 CpG methylase–treated normal human genomic DNA was used as a fully methylated control and Phi29-amplified normal human DNA was used as a fully unmethylated control. Additional "No template" (water) controls were run to ensure there was no contamination. We calculated fractional DNA methylation using the following formula:

$$fM_{\text{locus}} = (\text{positive test droplets}) / (\text{positive control droplets})$$

We compared the fractional methylation in the diagnostic specimen to the surgical specimen obtained after VEOX neoadjuvant chemotherapy to assess the pharmacodynamic activity of azacitidine delivered at different dose levels.

$$\Delta M_{\text{locus}} = fM_{\text{locus}}(\text{Surg}) / fM_{\text{locus}}(\text{Pre-VEOX})$$

Composite analysis of DNA methylation changes was calculated as the average change in DNA methylation for all informative loci. Differences in azacitidine-induced methylation changes were compared with treatment responses using ANOVA, Fisher exact test, and pairwise *t* tests of statistical significance. Expression of the TSG *HPP1* (*TMEFF2*) was evaluated by immunohistochemistry (IHC) in pre- and post-VEOX specimens when material was available.

Results

Patient characteristics

Twelve patients were enrolled between September 2011 and May 2014 (Table 2). Follow-up data were collected until June 1, 2015. The median age at study entry was 53.5 years (range, 40–84). The majority of patients were male (83%), ECOG performance status 1 (67%), with gastric or gastroesophageal junction cancers (67%), and lymph node involvement by endoscopic ultrasound (83%).

Neoadjuvant VEOX delivery

Eleven patients (92%) received all 3 planned cycles of VEOX and 1 received 2 cycles (see online only Supplementary Table S2). Seven patients required treatment delay due to toxicity (1 treated on DL 1, 6 treated on DL 2). Three patients (25%) received 100% of planned azacitidine, capecitabine, epirubicin, and oxaliplatin without delay. The mean percentage of planned dose received was 87% for epirubicin, 92% for oxaliplatin, and 91% for capecitabine. The indication for dose modification or delay was hematologic toxicity in 67% of patients and nonhematologic toxicity (nausea, vomiting) in 33% of patients. No patients required dose modifications for mucositis, neuropathy, or hand–foot syndrome.

Toxicity

All enrolled patients were evaluable for toxicity (Table 3). No DLT was observed in the first 3 patients treated and an additional 9 subjects were accrued to DL 2. The most common grade

Table 2. Preoperative clinical characteristics

Characteristic	N = 12 (%)
Age, y	
<60	8 (66.7%)
60–69	2 (16.7%)
≥70	2 (16.7%)
Median	53.5
Range	40–84
Sex	
Male	10 (83.3%)
Female	2 (16.7%)
ECOG PS	
0	4 (33.3%)
1	8 (66.7%)
Tumor type	
Esophageal	4 (33.3%)
Gastroesophageal junction	2 (16.7%)
Gastric	6 (50.0%)
Stage	
IIIB	3 (25.0%)
IIIA	6 (50.0%)
IIIB	3 (25.0%)
Preoperative lymph node involvement by endoscopic ultrasound	10 (83.3%)

Table 3. Treatment-related adverse events

Adverse effect	All patients (N = 12)		Dose level 1 (n = 3)		Dose level 2 (n = 9)	
	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4
	Abdominal pain	16.7%	0.0%			22.2%
Anemia	33.3%	0.0%			44.4%	0.0%
Anorexia	58.3%	8.3%	66.7%	33.3%	55.6%	0.0%
Constipation	8.3%	0.0%			11.1%	0.0%
Dehydration	8.3%	8.3%			11.1%	11.1%
Diarrhea	16.7%	0.0%			22.2%	0.0%
Dyspnea	8.3%	0.0%			11.1%	0.0%
Epistaxis	8.3%	0.0%			11.1%	0.0%
Fatigue	75.0%	16.7%	66.7%	0.0%	77.8%	22.2%
Dyspepsia	8.3%	0.0%			11.1%	0.0%
Hyperglycemia	8.3%	0.0%			11.1%	11.1%
Hypokalemia	8.3%	8.3%			11.1%	11.1%
Injection site erythema	8.3%	0.0%			11.1%	0
Leukopenia	58.3%	25.0%	33.3%	33.3%	66.7%	22.2%
Lymphopenia	8.3%	0.0%	33.3%	0.0%		
Mucositis	8.3%	0.0%			11.1%	0.0%
Nausea	66.7%	25.0%	33.3%	33.3%	77.8%	22.2%
Neutropenia	91.7%	66.7%	66.7%	66.7%	100%	66.7%
Neutropenic fever	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Peripheral neuropathy	33.3%	0.0%			33.3%	0.0%
Presyncope	8.3%	0.0%			11.1%	0.0%
Pulmonary embolus	8.3%	8.3%			11.1%	11.1%
Thrombocytopenia	50.0%	25.0%			66.7%	33.3%
Upper respiratory tract infection	8.3%	0.0%			11.1%	0.0%
Vomiting	16.7%	8.3%			22.2%	11.1%
Weakness	16.7%	0.0%			22.2%	0%
Weight loss	8.3%	0.0%			11.1%	0.0%

3–4 toxicities were neutropenia (66.7%), leukopenia (25.0%), thrombocytopenia (25.0%), and nausea (25.0%). Three patients were hospitalized during neoadjuvant treatment. Dehydration and hypokalemia (grade 4, DLT) occurred in an 84-year-old patient on day 21, cycle 2 (dose level 2). This patient received no further neoadjuvant therapy and upon recovery underwent R0 resection and remains recurrence free. A second patient treated on DL 2 developed a subsegmental pulmonary embolism (grade 4) 3 weeks after starting cycle 3, underwent complete resection (R0) demonstrating complete pathologic response to VEOX, and remains disease free. A third patient was hospitalized for grade 2 diarrhea, which promptly resolved after holding capecitabine. No patients developed febrile neutropenia. One patient received 2 doses of filgrastim for grade 4 neutropenia (ANC 200/ μ L) on day 8 of cycle 1 and went on to receive cycle 2 without delay. A second patient received 3 doses of filgrastim for grade 3 neutropenia (ANC 780/ μ L) on day 21 of cycle 1 and cycle 2 was delayed for 1 week. No patients received red blood cell transfusions or erythropoiesis-stimulating agents.

Response

After completing neoadjuvant VEOX, 11 of 12 patients underwent restaging PET/CT; the patient who developed a DLT after cycle 2 had CT imaging alone. Two patients (17%) had a radiographic complete response (CR), 6 patients (50%) had a partial response (PR), and the remainder ($n=4$, 33%) had stable disease (SD; Table 4).

All 12 patients achieved R0 resection after completion of neoadjuvant VEOX. Three (25%) patients had a complete

pathologic response, 5 patients (42%) had a partial pathologic response, and 4 (33%) had SD. Of the 10 patients with suspected nodal involvement at diagnosis, only 5 had pathologic nodal involvement at the time of resection. One patient was found to have a microscopic focus of metastatic peritoneal disease in the resected specimen.

Tumor DNA methylation

The degree of DNA methylation at each locus was tumor-specific. As expected, DNA methylation of *HIST1H2AA* was detected in all specimens tested. Tumor-associated methylation was observed most commonly at the *HPPI* locus followed by *TIMP3*, *ESR1* and then *CDKN2A* and *MGMT* (Fig. 1B). Most patients had methylation of multiple tumor loci in their specimens with the exception of one patient who had no detectable methylation at any locus but *HISTH2AA* (Fig. 1C).

VEOX chemotherapy induced DNA hypomethylation to a variable degree in a patient-specific manner. A hypomethylation ratio was calculated by dividing the normalized methylation observed in the surgical tumor sample with that found in pretreatment specimens for each locus tested. A composite hypomethylation ratio was then calculated from the average change in methylation observed at all informative cancer-associated loci (i.e., excluding *HIST1H2AA*). The likelihood of response (CR/PR) was greater if this hypomethylation ratio showed more than 2-fold reduction in tumor methylation ($P = 0.03$, Fisher exact test) after VEOX neoadjuvant therapy (Fig. 1D). Similarly,

Table 4. Surgical and pathologic response


Response	Patients (N = 12)
Radiographic response ^a	
CR	2 (16.7%)
PR	6 (50.0%)
SD	4 ^b (33.3%)
Extent of resection	
Curative/R0	12 (100%)
Pathologic response ^c	
CR	3 (25.0%)
PR	5 (41.7%)
SD	4 (33.3%) ^d
Pathologic lymph node involvement	5 (41.7%)
Tumor response	
CR	3 (25%)
PR (downstaged)	2 (16.7%)
Lymph node response	N = 10 (%)
Cleared	5 (50.0%)
Downstaged	1 (10.0%)
Pathologic stage	
NED	3 (25.0%)
IIA	1 (8.3%)
IIB	4 (33.3%)
IIIA	2 (16.7%)
IIIC	1 (8.3%)
IV	1 (8.3%)

^aRadiologic responses based on PERCIST criteria.

^bOne patient did not have a preoperative PET/CT; CT scan suggested SD.

^cComplete histologic response—no evidence of tumor in resected gastroesophageal specimen or lymph nodes; partial histologic response—residual cancer is identified in the resected gastroesophageal specimen or lymph nodes; SD—a <20% increase in the sum of the longest diameters of all measured lesions.

^dOne patient had a microscopic focus of metastatic disease in the resected specimen.

**Figure 1.**

VEOX decreased DNA methylation and induced reexpression of TSGs in tumor cells. **A**, Schematic of sample processing and bisulfite ddPCR analysis of DNA methylation in formalin-fixed, paraffin-embedded tumor specimens. **B**, Percentage of patients with detectable DNA methylation at each locus tested is shown. **C**, Percentage of tumor-associated loci tested (*HPP1*, *TIMP3*, *CDKN2A*, *ESRI*, and *MGMT*) with detectable DNA methylation is shown for each patient. **D**, Change in methylation in the surgically resected specimen compared with the diagnostic (pre-VEOX) specimen was compared for all loci. Shown here is the average change in DNA methylation at informative tumor-associated loci for each patient. The patients are ordered by the DNA methylation effect, and the bars are colored by the pathologic response (CR, black; PR, gray; SD, white). The red line indicates a 2-fold reduction in DNA methylation after neoadjuvant VEOX. Patients with greater than 2-fold hypomethylation had better responses in this data set ($P = 0.03$, Fisher exact test). **E**, Patients with CR or PR to neoadjuvant VEOX tended to have greater DNA hypomethylation of the TSGs tested (Student t test, $P = 0.057$). **F**, IHC stains for HPP1 demonstrate weak cytoplasmic staining of tumor cells (arrow) in pretreatment biopsy samples (left). Residual cancer in the posttreatment surgical resection specimen show more intense cytoplasmic staining for HPP1 (right, original magnification: 200 \times). **G**, DNA methylation at the HPP1 locus is shown for the matched IHC shown in **F**. These results show a greater than 10-fold reduction in DNA methylation after VEOX is associated with upregulation of HPP1 expression in tumor cells. ***, $P < 0.001$, Fisher exact test.

there was a trend toward greater hypomethylation in responding patients (CR + PR) compared with patients with SD ($P = 0.057$, t test, Fig. 1E). DNA hypomethylation of tumor loci was seen at all dose levels, but the analyses were not sufficiently powered to identify a dose-response relationship. These results suggest that neoadjuvant VEOX can induce epigenetic changes in gastric and esophageal cancers.

TSG reactivation

We directly observed hypomethylation of several TSGs after VEOX (Fig. 1A–E) and used IHC to evaluate whether hypomethylation was linked to induced TSG expression. We chose to evaluate *HPP1* (*TMEFF2*) because it was most commonly and most intensely methylated TSG in the tumors evaluated. We had sufficient tumor sections for analysis of the first 6 patients treated.

However, *HPP1* was not methylated in one of the pretreatment specimens (subject 1), and 3 subjects had no tumor in the resection specimen, precluding evaluation. Of the remaining 2 subjects (subjects 2 and 4), we observed greater staining for *HPP1* in the resected specimen compared with the pretreatment specimen (Fig. 1F). This supports the hypothesis that epigenetic priming can induce TSG expression during neoadjuvant chemotherapy.

Adjuvant therapy

Eleven patients received adjuvant therapy. Four patients completed 3 additional cycles of EOX and one received one cycle. Three patients completed 3 cycles of XELOX (capecitabine/oxaliplatin) and one patient received 2 cycles of capecitabine (Xeloda) and discontinued because of intolerance. One patient received cisplatin/taxol and another received concurrent chemoradiation with weekly carboplatin and taxol. One patient did not receive adjuvant therapy due to postoperative infection.

DFS and OS

After a median follow-up of 27.6 months, 6 of 12 patients remained disease-free and 9 of 12 are alive (Fig. 2A and B). All patients who had a complete histologic response remain alive and disease-free. (follow-up, 11.8–40.4 months). Median DFS was 20.5 months (95% CI, 8.7 months to upper limit not estimable); 12-month DFS was 83.3% (95% CI, 48.2%–95.6%), and 24-month DFS was 46.3% (95% CI, 17.2%–71.4%). Median OS was not reached; 24-month OS was 80.0% (95% CI, 40.9%–94.6%; Fig. 2). Patients with CR/PR had longer DFS than patients with SD (Fig. 2C, 12-month DFS = 58.3% vs. 25.0%), although the study was not powered to detect a statistically significant difference ($P = 0.48$).

Discussion

The motivating hypothesis of this study is that pretreatment with a DHA can hypomethylate tumor DNA and induce expression of TSGs in cancer cells, thereby sensitizing them to cytotoxic chemotherapy. We found that combining azacitidine with neoadjuvant EOX chemotherapy is safe and well-tolerated. Epigenetic-primed VEOX chemotherapy can induce hypomethylation and expression of candidate TSGs *in vivo*.

Although 5-azacitidine was synthesized more than 50 years ago, its development as an antineoplastic agent was hindered by excess toxicity observed at the high doses used in early studies (27–30). It was subsequently found that azacitidine can induce DNA hypomethylation at much lower doses (31) and is well-tolerated when used as a DHA at these doses even in frail patients with advanced myeloid neoplasms (32–37). The favorable toxicity profile allows DHAs to be combined with other agents. Such combinations are particularly attractive because studies have demonstrated that hypomethylating agents such as azacitidine can sensitize resistant cancer cells to cytotoxic agents both *in vitro* and *in vivo* (10, 11, 38–43). The precise mechanism underlying such chemosensitization is not well understood, but reactivated TSG expression is commonly implicated, as these genes often have roles in DNA repair, apoptosis, chemotherapy metabolism, and checkpoint control (44–46). Previously, we found that epigenetic priming using the DHA decitabine prior to intensive induction chemotherapy for AML was no more toxic than standard chemotherapy alone and we did not identify an MTD (16). Similarly, in




Figure 2.

Survival after VEOX therapy. **A**, OS is shown for all subjects after VEOX neoadjuvant chemotherapy ($N = 12$ patients, 3 deaths). Median OS not reached; 24-month OS = 80.0% (95% CI, 40.9%–94.6%). **B**, DFS is shown for all subjects ($N = 12$ patients, 6 recurrences). Median DFS = 20.5 months (95% CI, 8.7 months to upper limit not estimated); 12-month DFS = 83.3% (95% CI, 48.2%–95.6%); 24-month DFS = 46.3% (95% CI, 17.2% to 71.4%). **C**, DFS is shown by VEOX response. CR ($n = 3$ patients, 0 recurrences): 100% DFS. PR ($N = 5$ patients, 3 recurrences): 24-month DFS = 40.0% (95% CI, 5.2%–75.3%). SD ($N = 4$ patients, 3 recurrences): 24-month DFS = 25.0% (95% CI, 0.9%–66.5%). $P = 0.33$ by log-rank test.

this study, we found that azacitidine could be safely combined with EOX chemotherapy.

We did not observe a prohibitive increase in toxicity of the EOX neoadjuvant regimen with the addition of azacitidine. Median actual dose intensities observed with VEOX (Supplementary Table S2) were similar to those observed in REAL-2, (47), a phase III trial evaluating the efficacy of EOX in metastatic gastroesophageal cancer (epirubicin 91.9%, oxaliplatin 91.6%, and capecitabine 88.1%; median 6 cycles delivered). G-CSF support was not routinely used in the current study and the frequency of clinically significant neutropenia that we observed suggests that escalation of azacitidine beyond that tested in the current study may prove too myelosuppressive for routine use. For this reason, we recommend 75 mg/m² azacitidine for 5 consecutive days for further development.

The overall response rate for patients with advanced gastric and esophageal cancer receiving neoadjuvant EOX chemotherapy (~50%; ref. 47) was similar to that observed with VEOX (~67%). However, only 4% (8% of responders) of patients receiving EOX in prior reports achieved a CR, whereas 25% (44% of responders) of patients treated with VEOX had a pathologic CR, acknowledging that our sample size was small. All patients with a CR remain alive without recurrence suggesting that CR is a meaningful endpoint for assessing the quality of treatment response. Whether VEOX is truly superior to EOX neoadjuvant chemotherapy will require further investigation in the setting of a prospectively randomized study.

Our results support the hypothesis that azacitidine can hypomethylate tumor DNA and activate TSG expression. Prior studies have linked platinum resistance in ovarian cancer to hypermethylation and transcriptional silencing of key TSGs such as *RASSF1A* and have shown that platinum chemosensitivity can be restored to tumor cell lines by pretreatment with a DHA *in vitro* (12, 15, 48, 49). The demethylation and re-expression of *RASSF1A* in addition to *MLH1* and *HOXA11* were identified with "chemoresensitization," suggesting that epigenetic silencing of these key genes is a potential mechanism of platinum resistance. This approach has been sparsely studied in clinical trials but Fu and colleagues found that pretreatment with azacitidine (75 mg/m² × 5 days) can restore chemotherapy effect in platinum-resistant/refractory ovarian cancer without excess toxicity (19), and we have found that pretreatment with decitabine prior to cytarabine/daunorubicin chemotherapy was well-tolerated and had significant activity in a high-risk population of patients with AML (17). These results support the motivating hypothesis of this study and suggest that the DNA hypomethylation and TSG expression induced by VEOX we

observed could enhance tumor sensitivity and lead to a more favorable response rate after neoadjuvant chemotherapy.

In conclusion, epigenetic priming with azacitidine plus EOX was well-tolerated as a neoadjuvant approach for resectable gastroesophageal cancer. A multi-institutional phase II study is being developed using the established dose of azacitidine 75 mg/m² for 5 days prior to standard-dose EOX every 21 days. The higher-than-expected response rate is promising and this therapeutic approach warrants further investigation.

Disclosure of Potential Conflicts of Interest

M.A. Shah is a consultant/advisory board member for Lilly, Inc. A. Ocean reports receiving speakers' bureau honoraria from Genentech, Ipsen, and Merrimack. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: B.J. Schneider, J.M. Scandura

Development of methodology: B.J. Schneider, R. Yantiss, J.M. Scandura

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B.J. Schneider, M.A. Shah, K. Klute, A. Ocean, E. Popa, N. Altorki, M. Lieberman, R. Yantiss, D. You, A. Viale, J.M. Scandura

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B.J. Schneider, M.A. Shah, K. Klute, P.J. Christos, J.M. Scandura

Writing, review, and/or revision of the manuscript: B.J. Schneider, M.A. Shah, K. Klute, E. Popa, N. Altorki, M. Lieberman, R. Yantiss, P.J. Christos, R. Palmer, J.M. Scandura

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K. Klute, A. Schreiner, R. Palmer, J.M. Scandura

Study supervision: B.J. Schneider, J.M. Scandura

Other (slide staining): P. Kermani

Acknowledgments

Celgene provided Vidaza (5-azacitidine) for this study.

Grant Support

Research was partially supported by the Clinical and Translational Science Center at Weill Cornell Medical College (UL1-TR000457-06; to P.J. Christos), by the National Cancer Institute (CA159175; to J.M. Scandura), and Leukemia & Lymphoma Society (J.M. Scandura) and by the Madeline and Stephen Anbinder Clinical Scholar Award (B.J. Schneider).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 31, 2016; revised October 5, 2016; accepted October 25, 2016; published OnlineFirst November 10, 2016.

References

- Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. *Cancer* 2006;106:483–93.
- Kang C, Song JJ, Lee J, Kim MY. Epigenetics: an emerging player in gastric cancer. *World J Gastroenterol* 2014;20:6433–47.
- Hamilton JP, Sato F, Jin Z, Greenwald BD, Ito T, Mori Y, et al. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression. *Clin Cancer Res* 2006;12:6637–42.
- Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. *Cancer Res* 2001;61:3410–8.
- Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014;513:202–9.
- Wang JS, Guo M, Montgomery EA, Thompson RE, Cosby H, Hicks L, et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. *Am J Gastroenterol* 2009;104:2153–60.
- Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Kaminishi M, et al. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. *Cancer* 2009;115:3412–26.
- Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. *Clin Cancer Res* 2007;13:4225–32.
- Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after *in vivo* 5-azacytidine treatment in pediatric

- patients with refractory acute lymphocytic leukemia. *Cancer Chemother Pharmacol* 1989;24:203–10.
10. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. *Cancer Res* 2000;60:6039–44.
 11. Niitsu N, Hayashi Y, Sugita K, Honma Y. Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3. *Br J Haematol* 2001;112:315–26.
 12. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. *Am J Obstet Gynecol* 2009;200:177e1–9.
 13. Watanabe Y, Ueda H, Etoh T, Koike E, Fujinami N, Mitsuhashi A, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. *Anticancer Res* 2007;27:1449–52.
 14. Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, et al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. *Endocr Relat Cancer* 2009;16:401–13.
 15. Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH, et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. *Mol Cancer Ther* 2005;4:1505–14.
 16. Scandura JM, Roboz GJ, Moh M, Bose JR, Gergis US, Mayer SA, et al. Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML). *ASH Annual Meeting Abstracts* 2009;114:3079.
 17. Scandura JM, Roboz GJ, Moh M, Morawa E, Brenet F, Bose JR, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. *Blood* 2011;118:1472–80.
 18. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. *J Clin Oncol* 2007;25:4603–9.
 19. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. *Cancer* 2011;117:1661–9.
 20. Gollob JA, Sciami CJ, Peterson BL, Richmond T, Thoreson M, Moran K, et al. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. *Clin Cancer Res* 2006;12:4619–27.
 21. Schwartzmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. *Invest New Drugs* 2000;18:83–91.
 22. Pohlmann P, DiLeone LP, Cancelli AL, Caldas AP, Dal Lago L, Campos OJR, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. *Am J Clin Oncol* 2002;25:496–501.
 23. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 [cited 2009 May 28]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Bethesda, MD: NCI, NIH, DHHS. NIH Publication #09-7473.
 24. Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. *PharmacoEconomics* 2013;31:753–66.
 25. Yanagawa M, Tatsumi M, Miyata H, Morii E, Tomiyama N, Watabe T, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. *J Nucl Med* 2012;53:872–80.
 26. Sato F, Shibata D, Harpaz N, Xu Y, Yin J, Mori Y, et al. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. *Cancer Res* 2002;62:6820–2.
 27. Rivard GE, Mompalmer RL, Demers J, Benoit P, Raymond R, Lin K, et al. Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. *Leuk Res* 1981;5:453–62.
 28. Mompalmer RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. *Pharmacol Ther* 1985;30:277–86.
 29. Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A, et al. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. *Bone Marrow Transplant* 1989;4 Suppl 3:28–32.
 30. Richel DJ, Colly LP, Kluijn-Nelemans JC, Willemze R. The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. *Br J Cancer* 1991;64:144–8.
 31. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. *Cell* 1980;20:85–93.
 32. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. *J Clin Oncol* 2002;20:2429–40.
 33. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. *Cancer* 2006;106:1794–803.
 34. Kornblith AB, Herndon JEII, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, et al. Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. *J Clin Oncol* 2002;20:2441–52.
 35. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. *Proc Natl Acad Sci U S A* 2010;107:7473–8.
 36. Lubbert M, Minden M. Decitabine in acute myeloid leukemia. *Semin Hematol* 2005;42:S38–42.
 37. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. *J Clin Oncol* 2009;28:556–61.
 38. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, et al. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. *Cancer Res* 2005;65:11469–77.
 39. Kanda T, Tada M, Imazeki F, Yokosuka O, Nagao K, Saisho H. 5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. *Oncol Rep* 2005;14:975–9.
 40. Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan *in vitro* and *in vivo*. *Cancer Res* 1992;52:2180–5.
 41. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. *Int J Cancer* 2003;106:66–73.
 42. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. *Oncogene* 2001;20:5865–77.
 43. Qiu YY, Mirkin BL, Dwivedi RS. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. *Cancer Detect Prev* 2005;29:456–63.
 44. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. *Int J Cancer* 2005;114:683–95.
 45. Tamm I, Wagner M, Schmelz K. Decitabine activates specific caspases downstream of p73 in myeloid leukemia. *Ann Hematol* 2005;84 Suppl 1:47–53.
 46. Schimmer AD, Pedersen IM, Kitada S, Eksioğlu-Demiralp E, Minden MD, Pinto R, et al. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. *Cancer Res* 2003;63:1242–8.
 47. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008;358:36–46.
 48. Xie G, Hu C, Huang M. [Methylation status of RASSF1A and clinical efficacy of neoadjuvant therapy in patients with advanced epithelial ovarian cancer]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2011;36:631–3.
 49. Kassler S, Donninger H, Birrer MJ, Clark GJ. RASSF1A and the taxol response in ovarian cancer. *Mol Biol Int* 2012;2012:263267.

Clinical Cancer Research

Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response

Bryan J. Schneider, Manish A. Shah, Kelsey Klute, et al.

Clin Cancer Res Published OnlineFirst November 10, 2016.

Updated version	Access the most recent version of this article at: doi: 10.1158/1078-0432.CCR-16-1896
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2016/11/10/1078-0432.CCR-16-1896.DC1

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.